Bivalirudin and DES: a PCI strategy that pays.
作者信息
Applegate Robert J
机构信息
Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
出版信息
J Invasive Cardiol. 2007 Feb;19(2):69-70.
PMID:17268040
Abstract
摘要
相似文献
1
Bivalirudin and DES: a PCI strategy that pays.
J Invasive Cardiol. 2007 Feb;19(2):69-70.
2
3
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800. doi: 10.1016/j.jacc.2004.05.085.
4
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Am Heart J. 2006 Jul;152(1):149-54. doi: 10.1016/j.ahj.2005.09.007.
5
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
Heart. 2012 Apr;98(7):544-51. doi: 10.1136/heartjnl-2011-301323. Epub 2012 Feb 7.
6
Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Catheter Cardiovasc Interv. 2016 Feb 15;87(3):363-73. doi: 10.1002/ccd.26023. Epub 2015 May 22.
7
Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience.
JACC Cardiovasc Interv. 2009 Sep;2(9):871-6. doi: 10.1016/j.jcin.2009.06.015.
8
Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
Cardiovasc Ther. 2015 Aug;33(4):227-35. doi: 10.1111/1755-5922.12124.
9
Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
Curr Pharm Des. 2008;14(12):1197-204. doi: 10.2174/138161208784246162.
10
Economic impact of new interventional therapies: are we asking the right questions?
J Am Coll Cardiol. 2004 Nov 2;44(9):1809-11. doi: 10.1016/j.jacc.2004.08.010.
Zotero 插件